Sanofi's Dual Test: Tax Notice in India and a Costly Immunology Bet Before Q3

A regulatory notice landed on Sanofi's desk in India just as the French drugmaker was asking investors to swallow one of its largest pipeline commitments in years. On September 29, Sanofi India received a show-cause communication from local authorities demanding back taxes, interest, and penalties totaling 16.40 crore INR, tied to alleged discrepancies in its filings for fiscal year 2022/23. The subsidiary said it is reviewing the claim in detail and does not expect any material hit to its financial position or ongoing operations.

For the Paris-based parent, the exposure is modest. Yet the timing is awkward: global pharma investors are already fixated on regulatory and tax obligations inside international subsidiaries, wary that unplanned charges can eat into operating profit.

A Billion-Dollar Handshake With Regeneron

The bigger strategic story sits in immunology. Sanofi and Regeneron agreed to jointly develop and commercialize four long-acting antibodies that Regeneron discovered, a deal that carries a $1 billion upfront payment from Sanofi and up to $7 billion in success-based milestones spanning development, approval, and commercialization. Costs and future revenue are split down the middle.

The arrangement also buried earlier litigation that had strained relations between the two partners. Through it, Sanofi gains access to antibody technology it hopes will shore up its pipeline in high-margin therapeutic areas and open fresh growth avenues.

That rationale is not universally shared. An analysis by Reuters Breakingviews argues the four-antibody pact alone is unlikely to fully cushion the patent expirations looming over key revenue drivers, suggesting the company will need further transactions to reinforce its portfolio in time. Media reports point to investor unease over the financial weight of the commitment, compounded by Sanofi's continued heavy reliance on its blockbuster Dupixent.

Jefferies Stays Bullish, the Market Does Not

On October 1, Jefferies reaffirmed its constructive stance. Analyst Michael Leuchten kept a "Buy" rating and a 100-euro price target, arguing the expanded Regeneron agreement demonstrates the strategic progress being made under the company's new leadership.

The broader market has yet to buy into that optimism. Shareholders are weighing the long-term potential of the enlarged development programs against the substantial upfront investment and the inherent risks of clinical development cycles. On Monday, the stock closed at 69.96 euros, marking a new 52-week low and bringing its year-to-date decline to 16 percent. General pressure on French blue chips has added to the gloom.

An Industry Warning and a Looming Deadline

Worries about the competitiveness of Europe's research base are mounting across the sector. Sanofi joined top executives from leading European pharmaceutical companies in a joint appeal warning about the loss of investment in global competition.

The company now faces the delicate task of balancing expensive in-licensing against profitable research. On October 30, 2026, management will have to explain during its webcast on nine-month results how it intends to close the gaps in its pipeline for the long haul.